ArticleMMWR. Morbidity and mortality weekly report2023
Progress Toward Measles Elimination - African Region, 2017-2021.
Article in MMWR. Morbidity and mortality weekly report, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Evaluation of the measles surveillance system in Chereponi District, Ghana, 2019-2024.Public health in practice (Oxford, England) · 2026Article
- Article
- Article
- Article
- Cost-effectiveness and budget impact analyses of strategies to improve measles vaccination coverage in Kenya.PLOS global public health · 2026Article
- Safety, Immunogenicity, and Protective Efficacy in Rhesus Macaques of a Novel Recombinant Hemagglutinin Protein Measles Virus Vaccine.The Journal of infectious diseases · 2025Article
- Epidemiology: Temporal and spatial patterns of measles in Amhara Region, Ethiopia, 2019-2024: implications for targeted intervention.BMC infectious diseases · 2025Article
- Investigating persistent measles dynamics associated with population immunity in Chad: a national secondary data model analysis from 2011 to 2025.IJID regions · 2025Article
- Measles outbreaks in the United States in 2025: Practice, policy, and the canary in the coalmine.New microbes and new infections · 2025Article
- Reflections on 50 years of immunisation programmes in the WHO African region: an impetus to build on the progress and address the unfinished immunisation business.BMJ global health · 2025Article
- Vaccination Status and Incidences of Measles, Mumps, and Rubella - Worldwide, 2014-2023.China CDC weekly · 2025Article
- Epidemiological investigation of measles outbreak in a refugee settlement in Lamwo District, Uganda.The Pan African medical journal · 2025Article
- Trend of Measles Outbreak in Yemen From January 2020 to August 2024.International journal of general medicine · 2025Article
- Addressing the re-emergence and resurgence of vaccine-preventable diseases in Africa: A health equity perspective.Human vaccines & immunotherapeutics · 2024Review
- How did the introduction of the measles-containing vaccine second dose (MCV2) affect measles vaccine uptake? - evidence from Nigeria.Human vaccines & immunotherapeutics · 2024Article
- Predictors of measles-rubella vaccination status in the Savannah Region, Ghana: A cross-sectional study among caregivers of children aged 18-59 months.Vaccine: X · 2024Article
- On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000-2023, Namibia.Vaccines · 2024Article
- Tracking Measles and Rubella Elimination Progress-World Health Organization African Region, 2022-2023.Vaccines · 2024Article
- Possible Paths to Measles Eradication: Conceptual Frameworks, Strategies, and Tactics.Vaccines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, measles remains a major cause of disease and death; the highest incidence is in the World Health Organization African Region (AFR). In 2011, the 46 AFR member states established a goal of regional measles elimination by 2020; this report describes progress during 2017-2021. Regional coverage with a first dose of measles-containing vaccine (MCV) decreased from 70% in 2017 to 68% in 2021, and the number of countries with ≥95% coverage decreased from six (13%) to two (4%). The number of countries providing a second MCV dose increased from 27 (57%) to 38 (81%), and second-dose coverage increased from 25% to 41%. Approximately 341 million persons were vaccinated in supplementary immunization activities, and an estimated 4.5 million deaths were averted by vaccination. However, the number of countries meeting measles surveillance performance indicators declined from 26 (62%) to nine (22%). Measles incidence increased from 69.2 per 1 million population in 2017 to 81.9 in 2021. The number of estimated annual measles cases and deaths increased 22% and 8%, respectively. By December 2021, no country in AFR had received verification of measles elimination. To achieve a renewed regional goal of measles elimination in at least 80% of countries by 2030, intensified efforts are needed to recover and surpass levels of surveillance performance and coverage with 2 MCV doses achieved before the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.